Inside Asymchem's Technology-Led Expansion Of Oligonucleotide Capabilities

Oligonucleotides are redefining how complex diseases are treated, and meeting that promise requires more than manufacturing scale alone. In this video, Wu Mingyan, Chief Scientist for Oligonucleotides at Asichem, shares how decades of scientific and operational expertise are enabling a new generation of oligonucleotide development and production.

Drawing on more than 80 years of experience, the organization has built over 1.4 metric tons of annual oligonucleotide manufacturing capacity while continuing to invest deeply in R&D, talent, and infrastructure. Viewers gain insight into next-generation synthesis platforms designed to overcome scalability challenges, including advanced liquid-phase, convergent, and solid-phase approaches.

The discussion also highlights an in-house enzymatic ligation platform supported by more than 1,300 engineered enzymes, offering advantages in sustainability, efficiency, and the ability to produce increasingly complex sequences. Innovations in purification, such as multi-column counter-current solvent gradient systems, further improve throughput and performance. Together, these capabilities support fully integrated, end-to-end development from preclinical stages through commercial production — helping accelerate oligonucleotide therapeutics to patients.